AllPennyStocks.com Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock

Analysts raised their price targets on RARE stock after the FDA granted accelerated regulatory approval for its rare metabolic disease therapy.

Other Penny Stock Movers

A $1 Billion Crypto Deal Sends This Microcap Surging
The Scarcest Asset in Western Gold Exploration Is the Calendar
This Microcap Just Pulled Core From One of Copper's Last Frontiers
Most Popular
{{ index + 1 }}


Back to Top